缺血半暗带是急性缺血性脑卒中治疗的主要靶点，不断发展的影像学诊断技术虽能在有限的治疗时间窗内证实缺血半暗带的存在，但是技术的复杂性、高额的费用使得这些技术难以普及。血液标志物检测具有非创伤性、快速及价格经济等易被广泛接受的优点，已有大量血液标志物被研究应用于疾病的诊断或预后判断等，而针对缺血半暗带的血液标志物迄今尚未见相关报道。为此，本项目拟建立不同时间点大脑中动脉闭塞的大鼠模型，应用高通量的iTRAQ标记技术联合液相串联质谱，对血清蛋白和缺血半暗带的脑组织蛋白的表达差异进行分析，筛选在脑组织及血清中表达趋势一致的关键蛋白，利用蛋白质组学检测及生物信息学分析方法对其进行表达及功能的验证，以期获得缺血半暗带的血清特异性蛋白标志物。本项目的成功实施将有助于快速有效地确定缺血半暗带的存在，降低缺血性脑卒中溶栓治疗的成本，提高溶栓治疗的开展率，具有重要的科学意义和应用价值。

Ischemic penumbra is the main promising target for treating patients with acute ischemic stroke. Although multiple imaging techniques have been able to confirm the penumbra, the technology promotion has remained remarkably limited. Serum biomarker testing has the potential to serve as a valuable approach with non-traumatic, rapid, and cost effective. The majority of biomarker work has been performed for clinical application. However, no plasma biomarker of ischemic penumbra has been reported. For this purpose, we intend to establish focal brain ischemia which is produced by the occlusion of the right middle cerebral artery (MCAO) in rats. Using iTRAQ combined 2D LC-MS/MS, we examine the global expression profiling of protein. The protein showed a consistent trend for change in the brain tissue and serum will be validated by proteomics method and bio-information analysis to identify the potential serum penumbra biomarkers. This study will be capable to determine the existence of ischemic penumbra quickly and efficiently, reducing the cost and promoting thrombolysis in acute ischemic stroke.